Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Infectivity of PfSPZ Challenge (7G8 and NF54) in Healthy Adults
NCT02780154Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2016
- Primary completion
- Dec 2016
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PfSPZ Challenge in Plasmodium falciparum infection (5 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number and severity of local and systemic solicited and unsolicited reactogenicity symptoms and Number of serious adverse events. Started Aug 2016; status: completed.
02
Drugs
PfSPZ Challenge
03
Conditions
Plasmodium falciparum infection
Beyond the preview
Go deeper on NCT02780154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02780154.